Researcher
Jan Cools
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Hematology, Cancer biology
- See also: Cools J (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Molecular Biology of Leukemia (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2008 → Today - Laboratory of Molecular Biology of Leukemia (VIB-KU Leuven) (Division)
Member
From1 Dec 2017 → Today - Cools Lab (Research group)
Responsible
From1 Jan 2017 → Today - Faculty of Medicine (Faculty)
Member
From1 Oct 2004 → 30 Sep 2005 - Department of Human Genetics (Department)
Member
From1 Oct 1999 → 30 Nov 2017
Projects
1 - 10 of 62
- Molecular characterization of hyperactive T cell receptor signaling in peripheral T cell lymphoma to uncover druggable targetsFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of genetic events driving development of peripheral T cell lymphomaFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- GAINING INSIGHT IN THE MUTATIONAL PROFILE OF PT-DLBCL AND ASSESSING ITS BIOLOGICAL EFFECTS AND TRANSFORMING POTENTIALFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Degradation of CDK1 and HDACs as a strategy to treat T-cell malignanciesFrom1 Oct 2023 → TodayFunding: BOF - projects
- Uncovering mechanisms of TLX1/TLX3 oncogenic cooperation in leukemiaFrom1 Oct 2023 → TodayFunding: FWO senior postdoctoral fellowship
- EZH2 as a transcriptional activator in T-ALLFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- TLX transcriptional complexes in T-cell acute lymphoblastic leukemiaFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Deregulated mRNA transcription and protein translation in the transformation of normal T-cells to malignant cells.From1 Jan 2023 → TodayFunding: BOF - iBOF
- Mechanisms of resistance to current treatment of acute myeloid leukemiaFrom15 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Oncogene cooperation enhancing TLX1 positive leukemia developmentFrom1 Sep 2022 → TodayFunding: Other federal public and semi-governmental institutions
Publications
31 - 40 of 201
- The Fifth Year of HemaSphere(2021)
Authors: Jan Cools
- Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies(2021)
Authors: Inge Lodewijckx, Jan Cools
- Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia(2021)
Authors: Sofie Demeyer, Inge Govaerts, Jolien De Bie, Lucienne Michaux, Johan Maertens, Anne Uyttebroeck, Kim De Keersmaecker, Nancy Boeckx, Heidi Segers, Jan Cools
Pages: 801 - 811 - The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia(2020)
Authors: Delphine Verbeke, Sofie Demeyer, Jolien De Bie, Anne Uyttebroeck, Nancy Boeckx, Kim De Keersmaecker, Johan Maertens, Heidi Segers, Jan Cools
Pages: 5747 - 5758 - Combining targeted therapy and chemotherapy in acute lymphoblastic leukemia(2020)
Authors: Delphine Verbeke, Jan Cools, Heidi Segers
- FER and FES tyrosine kinase fusions in follicular T-cell lymphoma(2020)
Authors: Koen Debackere, Thomas Tousseyn, Lukas Marcelis, Daan Dierickx, Peter Vandenberghe, Lucienne Michaux, Jan Cools
Pages: 584 - 588 - Open Access is the Plan S Way Forward in Hematology Research(2020)
Authors: Jan Cools
- Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1(+) Leukemia (vol 19, pg 740, 2011)(2020)
Authors: Thomas Schmidt, Behzad Kharabi Masouleh, Sonja Loges, Sandra Cauwenberghs, Peter Fraisl, Christa Maes, Bart Jonckx, Kim De Keersmaecker, Maria Kleppe, Marc Tjwa, et al.
Pages: 135 - 136 - Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia(2019)
Authors: Delphine Verbeke, Nancy Boeckx, Kim De Keersmaecker, Johan Maertens, Anne Uyttebroeck, Heidi Segers, Jan Cools
- JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors(2019)
Authors: Inge Govaerts, Jan Cools
Patents
1 - 2 of 2